At a glance
Side-by-side comparison
| Metric |
CURE
Global X S&P Biotech ETF
|
HLTH
VanEck Global Healthcare Leaders ETF
|
|---|---|---|
| Snapshot | ||
| Provider |
Global X
|
VanEck
|
| Tracks index |
S&P Biotechnology Select Industry Index
|
—
|
| Categories |
US, Thematic
|
Intl, Thematic
|
| Listed since |
2021 (5 yrs)
|
—
|
| Fund size (AUM) |
$46m
|
$52m
|
| Cost & income | ||
| Management fee |
0.45%
|
0.45%
|
| Dividend yield |
0%
|
0.34%
|
| Franking |
0%
|
0%
|
| Turnover |
35%
|
—
|
| Tax drag | 0.84% | 0.11% |
| Returns |
Tax bracket
|
|
| 1-year return |
57.4%
net
|
4.9%
net
|
| 3-year return |
18.5%
net
|
4.7%
net
|
| 5-year return |
4.3%
net
|
-0.3%
net
|
| 10-year return |
—
|
—
|
| Risk | ||
| Volatility (3y) |
25.5%
|
12.6%
|
| Volatility (5y) |
24.9%
|
13.6%
|
| Volatility (10y) |
—
|
—
|
| Sharpe ratio (3y) |
0.63
|
0.1
|
| Sharpe ratio (5y) |
0.16
|
—
|
| Sharpe ratio (10y) |
—
|
—
|
| Bid/ask spread |
—
|
—
|
marks the strongest fund in each row. “net” shows the after-tax return at your selected bracket. “—” means we don’t have that data point yet.
Each fund at a glance
Frequently Asked Questions
CURE and HLTH are 2 Australian-listed ETFs we compare side by side. CURE carries the lower management fee (0.45%). Over 5 years, CURE has delivered the higher total return (4.3% a year). The table above breaks down fees, returns, income and risk for each.
CURE has the lower management fee at 0.45% a year, versus HLTH 0.45%.
Over the past 5 years, CURE has delivered the higher total return at 4.3% a year. Past performance is not a reliable indicator of future returns.
HLTH pays the higher at 0.34%. Remember distributions are taxed each year at your marginal rate.
HLTH is the larger fund by assets ($52m). Larger funds are typically more liquid and trade on tighter spreads.
Related comparisons
General information only, generated from each fund's published data — not personal financial advice. Past performance is not a reliable indicator of future returns. Consider your own circumstances or seek licensed advice before investing.